Eli Lilly

1 Lilly Corporate Ctr , Indianapolis, IN 46285

Public
Healthcare & Pharmaceuticals - Pharmaceuticals
over $1B
over 10K
(317) 276-2000


Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in approximately 130 countries. The Company?s products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. The Company?s new molecular entities (NMEs), which are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Ixekizumab, Necitumumab, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalum... (Source: SEC reports)


Competitor - 1/9
Which company is more competitive with Eli Lilly?




932 Contacts at this company
Kirk Hunt
Assistant General Counsel, Pricing
Robert Lee
Trademark Counsel
Matt Boehm
Distributor Sales Manager
Adam Phipps
Customer Experience and Payer ...
Thomas Turner
Consultant, Design Hub
Genevieve Ball
New Product Planning and Brand ?
Jeff Emmick
Vice President
Leonard Winneroski
Senior Research Scientist
Xiao Zhang
Senior Manager, Alzheimer?s Market Access ...

Oct 21, 2018 16:22:01
INDIANAPOLIS, Oct. 16, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Karen Walker as a new member, effective December 1, 2018. As [...]

Oct 5, 2017 21:37:13
INDIANAPOLIS, Oct. 5, 2017 /PRNewswire/ -- Today, a new shipment of commercial medicines, including more than 36,000 vials and pens of insulin, arrived in Puerto Rico. The delivery by Eli Lilly [...]

Sep 29, 2017 20:01:35
INDIANAPOLIS, Sept. 29, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a number of leadership changes, promoting several experienced Lilly leaders to executive roles, [...]

Aug 4, 2017 21:37:13
INDIANAPOLIS, Aug. 4, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, met [...]

Jul 7, 2017 21:37:40
INDIANAPOLIS, July 7, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the UK Supreme Court has decided in the litigation relating to alternative [...]

Get Started Today : Sign up in 20 seconds
Search with 20+ criteria.
Export results in seconds.
Bad emails?
No worry, we give two extras for every bad email.